Press Room

Event

DDL 2024 - Drug Delivery to the Lungs Conference

Start

Wednesday, December 11, 2024 - 08:00

End

Friday, December 13, 2024 - 17:00

Location: Edinburgh, Scotland

Booth Number: No. 168

Hovione is present at DDL Drug Delivery to the Lungs on December 2024, know more about the event and contact us to schedule a meeting

Hovione is excited to participate in the DDL Conference 2024, the Premier International Pulmonary & Nasal Drug Delivery Conference, from December 11-13 in Edinburgh.

Visit Hovione - Booth no. 168

Don't miss the opportunity to engage with our experts and learn more about our complete One-Site Solution that ensures that your inhalation and nasal therapies are engineered for success from start to finish.

Join Hovione Presentation

Thursday 12 December | Session 5 | 15:05 – 15:20

Finalists of The Pat Burnell Young Investigator Award

Paper Title: In vitro-In vivo Correlations (IVIVC) of Amorphous Solid Dispersions for Nasal Delivery
Patrícia Henriques, Scientist, R&D Inhalation and Advanced Drug Delivery

Abstract
Amorphous solid dispersions (ASD) for nasal delivery offer the opportunity to increase drug release performance, while using polymers with mucoadhesive properties. In spite of the current knowledge on formulation and characterization of nasal powders, scarce studies evaluate the potential of ASD. Additionally, the lack of translation between different in vitro methodologies and the lack of correlations between in vitro and in vivo results compromise the accurate and effective development of nasal powders.

Herein, spray dried ASD were manufactured and evaluated regarding in vitro drug release, ex vivo permeation and in vivo pharmacokinetic profile in Wistar rats. The results showed that ASD obtained by spray drying are able to improve drug release and permeation, ultimately resulting in faster drug absorption. This indicates that ASD for nasal delivery of poorly soluble drugs could be a suitable strategy to provide a faster onset of action. Additionally, the in vitro-in vivo correlations (IVIVC) between in vitro/ex vivo and in vivo pharmacokinetic parameters (t_max, C_max and AUC_1h), support the use of Franz diffusion cells to study drug release and permeation of nasal powder formulations.

Key learnings:

ASD of poorly soluble drugs for nasal delivery are a suitable strategy to provide a fast onset of action;
In vitro-in vivo correlations (IVIVC) are a valuable tool to support the use of in vitro methodologies as well as to guide formulation and process development.

Join Hovione Posters

Poster 81
Title: Dry Powder Antibody Formulations for Inhalation: Finding the Sweet Spot between High Dose and Protein Stability
Patrícia Henriques, Scientist, R&D Inhalation and Advanced Drug Delivery

Poster 110
Title: Breaking New Ground on Nasal Powders Performance Characterisation: Formulation & Device Integration
António Serôdio, Analytical Scientist, R&D Projects

Special Poster - Pat Burnell Nominee, Strathblane Foyer
Title: In vitro - In vivo Correlations (IVIVC) of Amorphous Solid Dispersions for Nasal Delivery
Patrícia Henriques, Scientist, R&D Inhalation and Advanced Drug Delivery

More about Inhalation and Nasal at Hovione
Find more about DDL 2024.

Let's discuss your project together.

Also in the Press Room

See All

Hovione has once again solidified its position as a top employer in all four of its manufacturing sites - Lisbon (Portugal), Cork (Ireland), East Windsor (NJ, USA), and Macau. The program highlights the company’s significant advancements in several critical areas, including Purpose & Values, Diversity, Equity & Inclusion (DEI), Employer Branding, and Recognition & Rewards, driven by sustained investment in people. This certification from the Top Employers Institute follows a rigorous audit process and underscores Hovione’s consistency in investing in people and world-class workplace practices, as well as the unwavering commitment of its more than 2,300 employees to the company's core purpose and values. “This recognition reflects the exceptional dedication and collaboration of the entire Hovione team,” said Jean-Luc Herbeaux, Chief Executive Officer. “Hovione is a development and manufacturing service company operating in one of the most demanding and regulated industries. We understand that our success is deeply rooted in our people. Together, as One Hovione, we are committed to continuously refining our people practices to foster a workplace that inspires motivation and enhances employee satisfaction, so that, every day, our team members bring their best selves to work, driving innovation and excellence at every step.” Macau, which became the first company in the region to achieve Top Employer certification last year, has successfully renewed the status, solidifying Hovione’s global leadership in workplace excellence. With its consistent Top Employer recognition, Hovione demonstrates that the talent strategy is perfectly aligned with the business strategy. Watch Ilda Ventura, Senior Vice-President of Human Resources and Member of the Management Board of Hovione, video about what this certification means for Hovione. For additional information, please read the press release.

News

The certification is granted to Hovione's four manufacturing sites for the third consecutive year.